GlassScriptPhysician profile
Taylor Washington
NPI 1699395186
$2,068.83
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $226 · 2023: $1,528 · 2024: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $592.48 | 2022-2024 | Caplyta |
| Abbvie INC. | $325.94 | 2023-2024 | |
| Corium, LLC | $240.94 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $186.23 | 2023-2024 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $142.28 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $85.31 | 2022-2024 | Austedo, Austedo Xr |
| Alkermes, INC. | $67.15 | 2023 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $62.50 | 2023-2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $60.40 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $58.60 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $50.85 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $40.59 | 2023 | Trintellix |
| Tris Pharma INC | $40.41 | 2023 | Dyanavel Xr |
| Lundbeck LLC | $34.01 | 2024 | Rexulti |
| Celgene Corporation | $24.99 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $22.01 | 2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $18.91 | 2023 | Hetlioz, Fanapt |
| Neos Therapeutics, LP | $15.23 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.